Abstract
Objective: We investigated whether there were sex differences in adverse reactions to an inactivated SARS-CoV-2 vaccine among medical staff in China.Methods: From 24 February to 7 March 2021 an online cross-sectional survey was conducted with a self-administered COVID-19 vaccine questionnaire among medical staff in Taizhou, China. In total, 1397 interviewees (1,107 women and 290 men) participated in the survey.Results: In our study, 178 (16.1%) women and 23 (7.9%) men reported adverse reactions following their first vaccination, and 169 (15.3%) women and 35 (12.1%) men reported adverse reactions following their second vaccination. After adjusting for confounding factors, adverse reactions to other vaccines, worry about adverse reactions, knowledge of the inactivated vaccine being used in the hospital, taking the vaccine for one's family proactively and receiving an influenza vaccination were significantly related to adverse reactions to both injections in women. In contrast, in men, concerns about adverse reactions independently increased the risk of adverse reactions following either vaccination, and a history of adverse reactions to other vaccines also increased the risk of adverse reactions to both injections.Conclusions: Sex differences in the frequency of reported adverse reactions to an inactivated SARS-CoV-2 vaccine and potential factors were demonstrated in a sample of medical staff.
Highlights
Coronavirus disease 2019 (COVID-19) has swept across the world since the discovery of the novel coronavirus in Wuhan in December 2019
We investigated whether there were sex differences in adverse reactions to an inactivated SARS-CoV-2 vaccine among medical staff in China
After adjusting for confounding factors, adverse reactions to other vaccines, worry about adverse reactions, knowledge of the inactivated vaccine being used in the hospital, taking the vaccine for one’s family proactively and receiving an influenza vaccination were significantly related to adverse reactions to both injections in women
Summary
Coronavirus disease 2019 (COVID-19) has swept across the world since the discovery of the novel coronavirus in Wuhan in December 2019. Vaccination to prevent severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection is considered the most promising approach for controlling the pandemic. In China, two inactivated virus vaccines (the Sinopharm vaccine and the Sinovac-CoronaVac) were the first approved for mass vaccination. Vaccines are widely available and vaccination rates are rising, people remain reluctant to get vaccinated immediately. Following a number of severe cases of blood clots after vaccination, some European countries have temporarily suspended AstraZeneca (AZD1222) vaccinations either fully or partially due to fear regarding thrombosis [2]. There is an urgent need to monitor and evaluate the safety of post-marketing vaccines as soon as possible
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
